Skip to Content
Jump to the top of the page

Investment Banking

The Quarterly Rx: Q2 2023 U.S. Biopharma Recap

Biopharma markets closed the first half of 2023 with renewed optimism and an encouraging outlook for the rest of the year. That comes as major market indices have trended upward—with biopharma emerging as the most heavily weighted sector in the Russell 2000—despite macro concerns following the regional banking crisis.

Public financing markets have warmed, but private companies continue to face challenging decisions amid a slow IPO market and selective private financing market. Simultaneously, SMID-cap M&A helped recycle capital in the sector.

William Blair’s Biopharma team shares perspectives in the Quarterly Rx: Q2 2023 U.S. Biopharma Recap.

Complete the form below to download your copy of the report.

Delivered to Your Inbox

Stay up-to-date with the latest William Blair news and insights

More News and Insights

  • William Blair Adds Senior Director in Europe

    William Blair announced today the expansion of the firm’s European team with the addition of Erik Westerink as senior director, Benelux, based in Amsterdam

    Read more
  • Year-End Wealth Planning and Philanthropy Strategies

    As 2026 draws to a close, now is the time to review your financial strategy and position yourself for success in the year ahead.

    Read more
  • Chroma Color Has Been Acquired by Wind Point Partners

    William Blair acted as the exclusive financial advisor to Chroma Color Corporation, a portfolio company of Arsenal Capital Partners, in connection with its sale to Wind Point Partners.

    Read more

Are you sure you want to leave?

Information contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.

For disclosure information, please visit www.williamblair.com/disclosures